Generic Medicine Info
Indications and Dosage
Uncomplicated gonorrhoea
Adult: 1 g as a single dose.

Uncomplicated urinary tract infections
Adult: 0.5 g 12 hrly given as deep IM or slow IV inj over 3-5 min.

Susceptible infections
Adult: 1-2 g 8-12 hrly given as deep IM or slow IV inj over 3-5 min, increased to 2-4 g IV 8 hrly in severe infections. Max: 2 g 4 hrly.
Child: ≥6 mth 50 mg/kg 6-8 hrly.
Renal Impairment
Loading dose: 0.5-1 g. Maintenance: According to CrCl and severity of infection.
CrCl (mL/min) Dosage
<5 0.25-0.5 g 24 hrly or 0.5-1 g 48 hrly, after dialysis.
5-49 0.25-1 g 12 hrly.
50-79 0.5-1.5 g 8 hrly.
Hypersensitivity to ceftizoxime.
Special Precautions
Patient w/ history of GI disease, particularly colitis; hypersensitivity to penicillins. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Rash, pruritus, fever; transient elevation in AST, ALT and alkaline phosphatase; transient eosinophilia, thrombocytosis; burning, cellulitis, phlebitis, pain, induration and tenderness at inj site, paraesthesia; nausea, vomiting, diarrhoea; transient rise in BUN and creatinine. Rarely, anaemia, neutropenia, leucopenia, thrombocytopenia, vaginitis, numbness.
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
IM/IV/Parenteral: B
Monitoring Parameters
Carefully monitor renal function.
Drug Interactions
Renal clearance reduced w/ probenecid.
Lab Interference
May develop positive Coomb's test.
Mechanism of Action: Ceftizoxime binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Time to peak plasma concentration: 1 hr.
Distribution: Widely distributed in body tissues and fluids; occur in CSF (therapeutic concentrations) when meninges are inflamed. Crosses the placenta and enters breast milk (low concentrations). Plasma protein binding: 30%.
Excretion: Via urine as unchanged drug w/in 24 hr. Plasma half-life: Approx 1.7 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Ceftizoxime, CID=6533629, https://pubchem.ncbi.nlm.nih.gov/compound/Ceftizoxima (accessed on Jan. 21, 2020)

Store at -20°C.
MIMS Class
ATC Classification
J01DD07 - ceftizoxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Buckingham R (ed). Ceftizoxime Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/11/2014.

Cefizox Solution (Astellas Pharma US, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Cephalosporins General Statement. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 25/08/2015.

Disclaimer: This information is independently developed by MIMS based on Ceftizoxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in